Cisplatin has been a mainstay of cancer chemotherapy since the 1970s. Despite its broad anticancer potential, its clinical use has regularly been constrained by kidney toxicities. This review details those biochemical pathways and metabolic conversions that underlie the kidney toxicities. A wide range of redox events contribute to the eventual physiological consequences of drug activities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963537 | PMC |
| http://dx.doi.org/10.1016/bs.acr.2021.03.008 | DOI Listing |
Publication Analysis
Top Keywords
kidney toxicities
8
cisplatin chemotherapy
4
chemotherapy renal
4
renal function
4
function cisplatin
4
cisplatin mainstay
4
mainstay cancer
4
cancer chemotherapy
4
chemotherapy 1970s
4
1970s despite
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!